Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Detalles Bibliográficos
Autores principales: Northend, Michael, Wilson, William, Osborne, Wendy, Fox, Christopher P., Davies, Andrew J., El-Sharkawi, Dima, Phillips, Elizabeth H., Sim, Hau Wui, Sadullah, Shalal, Shah, Nimish, Peng, Ying Ying, Qureshi, Iman, Addada, Juanah, Mora, Rocio Figueroa, Phillips, Neil, Kuhnl, Andrea, Davies, Elizabeth, Wrench, David, McKay, Pamela, Karpha, Indrani, Cowley, Anna, Karim, Richard, Challenor, Sarah, Singh, Vikram, Burton, Cathy, Auer, Rebecca, Williams, Chris, Cunningham, Joel, Broom, Angus, Arasaretnam, Anita, Roddie, Claire, Menne, Tobias, Townsend, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092410/
https://www.ncbi.nlm.nih.gov/pubmed/35020818
http://dx.doi.org/10.1182/bloodadvances.2021005953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092410/
https://www.ncbi.nlm.nih.gov/pubmed/35020818
http://dx.doi.org/10.1182/bloodadvances.2021005953

Ejemplares similares